Oral anti-hypertensives in pregnancy.
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial
Thomas Easterling, Shuchita Mundle, Hillary Bracken, Seema Parvekar, Sulabha Mool, Laura A Magee, Peter von Dadelszen, Tara Shochet,
Beverly Winikof Lancet 2019; 394: 1011–21
To compare 3 oral anti-hypertensive in the treatment of hypertension in pregnancy.
Hypertensive disorders of pregnancy is a major problem. In resource limited settings the administration of intravenous agents can be a significant burden on those limited resources. If oral agents are equally efficacious, this would have a big impact.
Open label randomised controlled trial
2 hospitals in Nagpur, India. One tertiary centre and its associated smaller hospital
894 Pregnant women
Inclusion; Pregnant women (28 weeks plus) with bp >160/110 (measured twice)
Exclusion; Emergency surgery needed, emerging eclampsia, known fetal abnormality, significant comorbidity (asthma, coronary heart disease, type 1 diabetes)
⅓ had no proteinuria, very few received magnesium or had deranged blood tests (<5% of each)
Administration of either Nifedipine(10mg, escalated as needed), labetalol (100mg, escalated as needed) methodolpa (1000mg, no dose escalation).
Magnesium prescribed as needed to both groups.
Usual clinican care; these patients received less than 2 litres of fluid in the first 6 hours. Only 2 percent received vasopressors.
Blood pressure control within 6 hours (systolic bp 120-150 and diastolic 70-100) with no adverse effects.
84% of the nifedipine group achieved good control within 6 hours without adverse events. This was significantly more than the methyldopa group (76%). There was no significant difference between the labetalol arm and the other treatment arms.
Adverse outcomes are rare and similar between groups.
These three medications are all good options for hypertensive pregnant patients with nifedipine seeming the most effective.
They also draw attention to the positive outcomes with frequent bp measurements and early administration of oral medications.
Expanded numbers to ensure sufficient power to detect difference.
Intention to treat analysis
No direct comparison to intravenous therapy
Largely outpatient non emergency study.
Unclear exactly what type of unit the patients were treated in, presumably a maternity unit; uncertain if applicable to an emergency generalist setting.
My humble opinion
Reassuring that methyldopa (the medication I am most used to ) and the simplest to administer is effective in reducing hypertension quickly in a stable pregnant hypertenisve patient.
However, this is a very well cohort of patients with few complications that I would expect to respond well to oral medications, for a non-specialist it is difficult to know when to try and get away with oral therapy or to resort to IV. As an emergency physician, it would be nice to see this result repeated in a cohort who were slightly more unwell.